For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Zoetis Inc. (ZTS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +33 (−100…+100 Quality+Value blend) · Quality 69 · Value 4 · Sentiment -53 (timing only, not weighted) · Composite fair value $84.55 vs $73.54 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Zoetis Inc.
ZTS NYSEZoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. Its products serve both companion animals, such as dogs, cats, and horses, and livestock, including cattle, swine, poultry, fish, and sheep. Zoetis offers a broad portfolio spanning parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation therapies, and nutritional and other non-pharmaceutical products, supported by point-of-care diagnostic tools, laboratory services, and monitoring technologies. The company markets its solutions primarily to veterinarians, livestock producers, and pet owners, playing a key role in supporting animal health, food production efficiency, and pet care standards worldwide. Zoetis Inc. operates across the United States and international markets and is headquartered in Parsippany, New Jersey.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.02
Total Equity: $3.33B
Shares: 443,835,000
Total Debt: $9.04B
Cash: $2.31B
EBITDA: $4.91B
Total Debt: $9.04B
Cash: $2.31B
Revenue: $9.47B
Revenue: $9.47B
Revenue: $9.47B
Total Equity: $3.33B
Tax Rate: 20.4%
Equity: $3.33B
Total Debt: $9.04B
Cash: $2.31B
Current Liabilities: $2.24B
Long-Term Debt: $9.04B
Total Debt: $9.04B
Total Equity: $3.33B
Shares: 443,835,000
Shares: 443,835,000
CapEx: -$621.00M
Shares: 443,835,000
Stock Price: $72.51
Net Income: $2.67B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 13, 2026 12:28am (10d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Cost of Revenue | $2.3B | $2.5B | $2.6B | $2.7B | $2.7B |
| Gross Profit | $5.5B | $5.6B | $6.0B | $6.5B | $6.8B |
| Operating Expenses | $2.0B | $2.0B | $2.2B | $2.3B | $2.4B |
| Operating Income | $3.5B | $3.6B | $3.8B | $4.2B | $4.4B |
| Net Income | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| EBITDA | $3.9B | $4.1B | $4.3B | $4.7B | $4.9B |
| EPS | $4.29 | $4.51 | $5.08 | $5.47 | $6.03 |
| EPS (Diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 5:02pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.5B | $3.6B | $2.0B | $2.0B | $2.3B |
| Total Current Assets | $6.9B | $7.5B | $6.3B | $6.0B | $6.8B |
| Total Assets | $13.9B | $14.9B | $14.3B | $14.2B | $15.5B |
| Current Liabilities | $1.8B | $3.2B | $1.9B | $3.4B | $2.2B |
| Long-Term Debt | $6.6B | $6.6B | $6.6B | $5.2B | $9.0B |
| Total Liabilities | $9.4B | $10.5B | $9.3B | $9.5B | $12.1B |
| Total Equity | $4.5B | $4.4B | $5.0B | $4.8B | $3.3B |
| Retained Earnings | $7.2B | $8.7B | $10.3B | $12.0B | $13.7B |
Cash Flow (Annual)
Last updated: Aug 13, 2026 12:28am (10d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.2B | $1.9B | $2.4B | $3.0B | $2.9B |
| Capital Expenditure | -$477.0M | -$586.0M | -$732.0M | -$655.0M | -$621.0M |
| Free Cash Flow | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | -$600.0M | $1.3B | -$1.4B | $0 | $498.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$743.0M | -$1.6B | -$1.1B | -$1.9B | -$3.2B |
| Net Change in Cash | -$119.0M | $96.0M | -$1.5B | -$54.0M | $325.0M |
Growth Trends (YoY %)
Last updated: Aug 13, 2026 12:28am (10d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.9% | +5.7% | +8.3% | +2.3% |
| Gross Profit Growth | +2.8% | +6.3% | +9.3% | +4.0% |
| Operating Income Growth | +4.2% | +5.9% | +10.1% | +4.8% |
| Net Income Growth | +3.8% | +10.9% | +6.1% | +7.5% |
| EBITDA Growth | +4.1% | +5.9% | +9.1% | +4.1% |
Dividend History (Last 20)
Last updated: Aug 13, 2026 12:11am (10d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-20 | $0.53 | — | — | — |
| 2026-04-20 | $0.53 | — | — | — |
| 2026-01-20 | $0.53 | — | — | — |
| 2025-10-31 | $0.50 | — | — | — |
| 2025-07-18 | $0.50 | — | — | — |
| 2025-04-21 | $0.50 | — | — | — |
| 2025-01-21 | $0.50 | — | — | — |
| 2024-10-31 | $0.43 | — | — | — |
| 2024-07-18 | $0.43 | — | — | — |
| 2024-04-18 | $0.43 | — | — | — |
| 2024-01-18 | $0.43 | — | — | — |
| 2023-10-31 | $0.38 | — | — | — |
| 2023-07-20 | $0.38 | — | — | — |
| 2023-04-20 | $0.38 | — | — | — |
| 2023-01-19 | $0.38 | — | — | — |
| 2022-10-31 | $0.33 | — | — | — |
| 2022-07-20 | $0.33 | — | — | — |
| 2022-04-20 | $0.33 | — | — | — |
| 2022-01-19 | $0.33 | — | — | — |
| 2021-10-28 | $0.25 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-20 09:17Recovery pays +16%; another quarter like the worst recent one costs 12%. Ratio 1.3:1.
| Case | Growth | Margin | Fair value | vs price ($73.54) |
|---|---|---|---|---|
| Bull — recovery | +4% | 31.8% | $85.33 | +16% |
| Base — stabilizes | +3% | 27.7% | $71.77 | -2% |
| Bear — keeps slipping | +1% | 23.5% | $59.29 | -19% |
| Stress — last quarter repeats | -0% | 27.7% | $64.77 | -12% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-13Clinic throughput, not pet-owner willingness to pay, is the binding constraint on companion-animal drug consumption; AI triage, image interpretation (Vetscan Imagyst-style) and clinic admin automation raise visits-per-vet, and every incremental visit pulls Zoetis parasiticides, derm and monoclonals with it.
The diagnostics leg — where Zoetis is pushing growth against IDEXX and Mars — is the one part of the portfolio that is mostly information processing; AI-native image/lab interpretation can be bundled cheaply into practice-management software or reference labs, compressing the per-test economics Zoetis is building on.
Whether AI-assisted diagnostics accrues to Zoetis as therapy attach-rate and razor-blade consumable volume, or leaks to whoever owns the clinic software layer. Watch diagnostics segment organic growth and Imagyst installed-base/test-volume disclosure versus instrument placements alone.
FDA-CVM/USDA/EMA approved dossiers across 100+ countries, biologics and vaccine manufacturing plants, and a direct veterinarian field force with prescription-channel trust — none of which get cheaper because code does.
AI Lens thesis
AI reaches Zoetis on three separate wires with different signs: R&D (cheaper target/antibody design for animal biologics — modest, since the gating item is field trials and regulatory review, not molecule ideation); diagnostics (genuinely software-exposed, where AI both enables Zoetis's own point-of-care franchise and lets outsiders interpret images without owning the instrument); and demand (AI relieving the veterinarian-hours bottleneck and pet-owner triage friction, which is volume-accretive to a company whose revenue unit is doses and tests, not seats or hours). Because the monetized unit is a physical dose administered under a prescription and a liability chain, cheap intelligence cannot disintermediate the sale — it can only re-route the channel toward online pharmacies, which changes Zoetis's mix and price transparency more than its unit demand. Net: the shield holds, the upside is real but second-order, and the share-loss problem visible in the numbers is a patent/product-safety/competition story that AI neither caused nor cures.
What the market may be underestimating
Upside Veterinary labor scarcity is the real ceiling on companion-animal spend; if AI adds even 10-15% effective clinic capacity, Zoetis captures that as pure volume on 72% gross margin product with no incremental commercial spend.
Downside AI-mediated pet-owner triage plus price-transparent online pharmacies erodes the vet's role as the point of purchase, turning branded parasiticides into shelf-compared SKUs and weakening the pricing power that has driven operating margin from 44.7% to 46.7%.
Outcome range spread 32
Claude Reading
Looking at the raw print first: ZTS is doing $9.47B TTM revenue growing ~5% annually, with net margins that have held between 25-30% every quarter for two years. The most recent quarter (Q2 2026) shows $2.47B rev / $691M NI — flat YoY on revenue ($2.47B vs $2.47B in Q2 2025) and down slightly on earnings ($691M vs $726M, margin 28% vs 29.3%). That's the tell: revenue has genuinely stalled at the ~$2.4B quarterly run-rate for six quarters running. The 5.3% revenue CAGR is backward-looking; the forward run-rate is closer to 2-3%. FCF of $2.28B on a $31B market cap is a 7.3% FCF yield, and the 12.2x P/E on a business with 35% ROIC and 72% gross margins is genuinely cheap on absolute terms.
Where I diverge from the synthesis: the "slight upside to $76.88" verdict feels roughly right in direction but the composite fair value of $85.65 leans on growth assumptions the quarterly tape is actively contradicting. Market Forces' "deteriorating compounder / value trap" framing is too dark — a business generating $2.28B FCF with 47% operating margins isn't deteriorating, it's plateauing. But the Thesis Evaluation's neutral zero score is intellectually honest, and the bear point about D/E going from 1.32 to 2.71 is the single most important number in this file that nobody is stressing enough. Total debt $9.04B against $3.33B equity, funded partly by buybacks — that's the classic late-cycle mature-pharma playbook where financial engineering substitutes for organic growth. It works until it doesn't, and it caps multiple expansion.
The contrarian case against my own mild-bull lean: if companion animal is genuinely hitting a 3% growth ceiling (plausible given pet adoption normalization post-COVID and consumer discretionary weakness on vet visits), then this is a $9.5B revenue business growing 2-3% with maybe 50-100bps of annual margin risk from GLP-1-style competitive dynamics in parasiticides (Librela/Solensia face real competition, and Simparica Trio's moat isn't infinite). At 3% growth and flat margins, DCF fair value is closer to $65-70, not $85. The insider "activity" is entirely small award grants — 45 to 616 shares each — this is routine comp vesting, not a signal. The thesis eval flagging "coordinated insider buying" as a 58-weight bull point is wrong; there are no open-market purchases here. That's a model error worth calling out.
Net read: I partially agree with the synthesis direction but think the magnitude is overstated. At $72.51, you're paying 13.6x FCF for a 47% operating margin animal health monopolist with real but decelerating growth and a levered balance sheet. That's fair-to-slightly-cheap, not a screaming buy. Fair value band is $70-80 depending on whether you believe organic growth reaccelerates to 5%+ or settles at 2-3%. The re-rating from $160 to $72 already priced in the deceleration; further downside requires either an actual earnings miss or a leverage-driven credit event, neither imminent. Upside requires either a pipeline surprise (parasiticide franchise extension, new companion animal indication) or multiple re-rating back toward specialty pharma comps at 18-20x, which needs a growth catalyst that isn't visible in the Q2 2026 print. I'd own it for the FCF yield and dividend, not for the compounding story — the compounding story is what got crushed from $160 to $72 and it isn't coming back at these growth rates.
GPT Reading
What jumps out first is how little operational damage there is in the numbers relative to how hard the stock has been de-rated. Zoetis has grown revenue from $7.78B in 2021 to $9.47B in 2025, a 5%+ annual clip, while net income rose from $2.04B to $2.67B and operating income from $3.47B to $4.42B. This is not a business showing obvious franchise erosion: gross margin is still 71.8%, operating margin 46.7%, and net margin 28.2%, which are elite for a large-cap healthcare name. The quarterly run-rate is similarly steady rather than crumbling. The last four quarters sum to roughly $9.53B of revenue and about $2.65B of net income, almost exactly in line with the 2025 full-year earnings power. Even the “slowdown” looks mild: the most recent quarter at $2.47B was flat year over year against a tough compare, while the March quarter grew from $2.20B to $2.26B and net income held around the mid- to high-20s margin band. That profile does not scream value trap.
At $72.51, the valuation looks too cheap for that quality, and I think the headline multiples are telling the right story more than the scarier narrative. A ~$31.1B market cap against $2.67B of annual net income is about 11.7x earnings; against $2.28B of free cash flow it is about 13.7x FCF; and enterprise value is only about 8.0x EBITDA. For a company earning ~35% ROIC and ~17% ROA with a current ratio above 3x, those are depressed multiples unless one assumes a real step-down in growth or margins. The market seems to be capitalizing Zoetis as a no-growth or low-single-digit grower with some hidden fragility, but the reported numbers still show compounding, not decay. Importantly, this is not a low-quality earnings story: $2.90B of operating cash flow against $2.67B of net income is healthy conversion, and after $621M of capex the company still throws off over $2.2B of annual FCF. If that cash generation merely holds flat, the current price is not demanding.
The balance sheet is the one legitimate blemish, but even there I think the stock discount overshoots the risk. Debt of $9.04B against $2.31B of cash leaves net debt around $6.7B, which is meaningful relative to $3.33B of equity and explains the optically high 2.7x debt-to-equity and nearly 80% ROE. But the business earns enough that leverage is manageable rather than thesis-breaking: operating income of $4.42B and EBITDA implied by the EV multiple suggest substantial debt service capacity. In other words, leverage has juiced returns metrics, but it has not yet overwhelmed the economics. For a stable animal-health leader with durable pricing, recurring demand, and margins this high, a modestly levered balance sheet should not force a 12x earnings multiple unless deterioration is imminent. I don’t see imminent deterioration in the data provided.
The best bear case is that the market is sniffing out a business moving from “premium compounder” to “mature cash cow” faster than the income statement admits. Annual revenue growth slowed to 2.3% from 2024 to 2025, and the recent quarterly pattern is basically flat around $2.4B to $2.5B. If organic growth settles near 2%-3% while buybacks or capital structure effects flatter per-share metrics, then 12x earnings is less absurd than it looks. The leverage also matters more in that scenario: with debt at $9.04B and equity only $3.33B, management has less room for capital allocation mistakes, and the high ROE is clearly balance-sheet-aided. I also would not give any weight to the insider tape here; these are award grants, not open-market buys, so they do not signal conviction. A smart skeptic would say this is simply a very good business now priced like a very good but ex-growth business, and there is not enough evidence in two or three quarters of flattish sales to call that wrong.
What would change my mind is straightforward. If the next few quarters show revenue rolling over below the $2.3B-$2.4B level with net margin slipping toward the low-20s, then the current multiple is a value trap and deserves to stay compressed. Likewise, if free cash flow falls materially below $2.0B annualized while debt remains around current levels, I would stop treating the leverage as benign. On the other hand, if Zoetis can keep revenue around $9.6B-$9.8B, preserve operating margin near 45%-47%, and continue generating $2.3B+ of FCF, the stock should not sit at 11x-12x earnings for long. My bias is that the market has overreacted to deceleration and is undervaluing a still-exceptional franchise.
Grok Reading
The numbers describe a fortress P&L that the market has decided to price like a fading generic. Zoetis just put up $9.47B of 2025 revenue at a 71.8% gross margin, 46.7% operating margin and 28.2% net margin, converting that into $2.90B of operating cash and $2.28B of free cash flow after a modest $621M capex burden. Trailing net income of $2.67B against a $31.1B equity value is a 12.2x P/E and roughly 7.3% FCF yield, with a 2.8% dividend tacked on. Those are commodity-drug multiples on a business that still prints mid-to-high-20s net margins quarter after quarter—latest print $2.47B revenue and $691M net income at 28%. Five-year revenue CAGR of 5.3% and earnings CAGR of 6.8% are not spectacular, but they are real, and FCF has compounded faster at 18.7% as working capital and capex stayed disciplined. The story the raw data tell is simple: cash generation and margin durability remain intact even as top-line growth has cooled to a recent 2.3% YoY pace and a flat $2.47B June quarter versus the year-ago period.
What stands out against the models is how cleanly the de-rating has outrun the fundamental deceleration. The stock has been cut from a prior premium-pharma regime (~30x) to 8.0x EV/EBITDA and 3.4x sales while operating income still climbed from $3.47B in 2021 to $4.42B in 2025 and net margins held or expanded. The balance sheet is the legitimate scar: $9.04B of debt against only $3.33B of equity and $2.31B of cash produces a 2.71 debt-to-equity ratio and an optically stellar 80% ROE that is clearly leverage-amplified. That capital structure almost certainly funded buybacks, and it leaves less cushion if growth stalls further. Yet ROIC is still 35%, the current ratio is 3.0, and absolute free cash flow covers interest and dividends with room to spare. I also discount the “coordinated insider buying” bull point in the thesis layer—every recent filing is an A-Award grant, not open-market accumulation—so that signal is noise. The quantitative slight-upside call toward the mid-$70s to mid-$80s looks directionally right; the “deteriorating compounder / value trap” market-forces read overweights the leverage narrative relative to the still-excellent cash conversion and margin stability actually visible in the statements.
The strongest case against owning it here is that the growth engine has already downshifted into the zone the bears warned about. Revenue growth of 2.3% trailing, a literally flat June quarter, and a five-year top-line CAGR that has compressed toward the low single digits mean the market may simply be correctly marking this as a 1–3% terminal grower. If companion-animal spending saturates or livestock cycles turn, that 12x multiple stops looking cheap and starts looking like fair value for a no-growth cash cow carrying net debt of roughly $6.7B. The thin equity base magnifies any earnings miss into a balance-sheet event, and FCF growth will inevitably converge toward the slower earnings growth once buyback-driven optical leverage fades. A smart opponent would also note that 95% of the price is already explained by DCF in the narrative layer—there is no hidden story premium to collapse, but equally little margin of safety if the 28% net margin proves peak-cycle. I weigh those points seriously, but I still put more weight on the fact that margins have not compressed, FCF quality remains high, and an 8x EV/EBITDA / 7%+ FCF yield already embeds a great deal of that pessimism.
I would flip to a fair-value or overvalued stance if the next two reported quarters show revenue growth stuck at or below 1–2% accompanied by any meaningful operating-margin erosion below the mid-40s, or if net debt rises further without a corresponding acceleration in organic growth. Conversely, a clean re-acceleration to 5%+ organic revenue growth with stable margins, or a visible multi-quarter debt pay-down that rebuilds the equity base, would push me from moderate to high conviction on the undervaluation.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Zoetis shows the profile of a durable specialty pharma: revenue compounded from $7.78B (2021) to $9.47B (2025), gross margin expanded from 70.4% to 71.8%, and operating margin climbed steadily from 44.7% to 46.7%. Net income rose every year to $2.67B and FCF reached $2.28B in 2025, with OCF/NI at 1.05x and accruals at -1% of assets - earnings are backed by cash. Beneish M of -2.44 and Altman Z of 4.73 corroborate clean books. Capital allocation favors shareholders: diluted share count fell from 476.7M to 443.8M (-1.8% CAGR), SBC is a trivial 0.9% of revenue, and buybacks run 25x SBC. The offset is a net debt position of roughly $6.7B against $2.3B cash; leverage is real but very serviceable against $2.3B in annual FCF and 46.7% operating margins. Insider tape shows only routine equity awards - no directional buys or sells to read into. Taken together this is a high-quality mature earner with expanding margins, disciplined share count, and pristine earnings quality. The one thing keeping it out of fortress territory is the leveraged balance sheet - net debt rather than net cash - which limits it to a constraint rather than a cushion.
Verify before trusting this (5)
- Debt maturity ladder and average interest rate on the ~$9B gross debt
- Organic vs FX/acquired revenue growth in 2025 to confirm underlying demand
- Concentration risk in key franchises (Simparica Trio, Librela, Apoquel) and patent/exclusivity timelines
- Any pending litigation or regulatory issues on newer monoclonal antibody products
- R&D productivity and pipeline replenishment given mature-earner classification
Without a fresh DCF or peer multiple set in the brief, I anchor on what Zoetis is: the category-leading animal health pure-play with durable companion-animal growth (Simparica Trio, Librela, Solensia), high-teens to low-20s operating margins, and consistent double-digit EPS growth historically. That profile typically deserves a premium multiple (mid-20s to low-30s P/E). At $73.54 and a roughly $30B market cap, the stock is well off its prior highs near $200, suggesting the market has already repriced growth expectations lower on Librela safety headlines and slowing companion-animal spend. That derating brings valuation from stretched toward reasonable, but not into obvious-bargain territory. The deserved value on a normalized earnings power basis sits broadly in line with today's price - call it a mid-$60s to mid-$80s band depending on how much of the Librela overhang and consumer softness one treats as permanent versus transient. That is fair, not cheap. To underwrite meaningful upside I would want either a lower entry that builds in a real margin of safety, or evidence that Librela concerns are contained and companion-animal script growth is reaccelerating. Neither is in hand at $73.54.
Verify before trusting this (5)
- Latest quarterly organic revenue growth by species (companion vs livestock)
- Librela US label status, adverse-event disclosures, and script trajectory
- Updated full-year guidance and operating margin trajectory
- Buyback pace and net leverage at current share price
- Peer multiples (IDXX, ELAN) for relative anchoring
The market tape is mildly risk-on (VIX 14.6, S&P near highs), but that lift barely reaches ZTS. With a 0.73 beta and a defensive healthcare profile, this name doesn't ride euphoric tapes; it lives or dies by its own narrative, and that narrative just cracked. Two consecutive guide-downs (the May -21.5% crash to a 7-year low, then the August full-year cut) have punctured the 'durable steady-compounder' story that justified the premium multiple. Intensity is minimal and durability was rated durable, but the recent news flow is actively eroding both. Analyst tone is 'cautiously optimistic' - code for waiting-and-seeing, not defending - and the Barchart piece explicitly frames ZTS as an underperformer. Michael Burry adding to his ZTS stake is a mild contrarian tailwind (value-name signaling) but it's paired in the same headlines with his AI-bubble shorts, so the tape is coding ZTS as a defensive hide-out, not a story stock people chase. Net: the narrative is fading, not broken outright, while macro (10y at 4.7%, market PE 26) offers no rerating help for a mature healthcare compounder. Pressure leans negative but not violent - a persistent crosswind, not a collapse.
Verify before trusting this (5)
- Next quarterly print - does companion animal weakness stabilize or deepen
- Any competitive commentary on Librela / parasiticide franchises
- Analyst target revisions - watch for downgrades that would confirm narrative decay
- Whether Burry's stake grows or exits at next 13F - could shift the contrarian read
- Sector rotation into defensives if the risk-on tape falters
AI reaches Zoetis on three separate wires with different signs: R&D (cheaper target/antibody design for animal biologics — modest, since the gating item is field trials and regulatory review, not molecule ideation); diagnostics (genuinely software-exposed, where AI both enables Zoetis's own point-of-care franchise and lets outsiders interpret images without owning the instrument); and demand (AI relieving the veterinarian-hours bottleneck and pet-owner triage friction, which is volume-accretive to a company whose revenue unit is doses and tests, not seats or hours). Because the monetized unit is a physical dose administered under a prescription and a liability chain, cheap intelligence cannot disintermediate the sale — it can only re-route the channel toward online pharmacies, which changes Zoetis's mix and price transparency more than its unit demand. Net: the shield holds, the upside is real but second-order, and the share-loss problem visible in the numbers is a patent/product-safety/competition story that AI neither caused nor cures.
None surfaced.
Verify before trusting this (8)
- biologics share of revenue mix
- nutraceutical/DTC substitution trends
- label-expansion approvals
- manufacturing capex and capacity adds
- country registration count
- field-force productivity metrics
- volume versus price contribution split
- doses per treated animal trends
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 13, 2026, ZTS was $73.54. We expect it to be $82.80 by Feb 2027, and we consider it great value under $60.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 13, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.